Your browser doesn't support javascript.
loading
All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma.
Fante, Matthias A; Harrer, Dennis C; Zartner, Barbara; Lüke, Florian; Mayer, Stephanie; Menhart, Karin; Reichle, Albrecht; Herr, Wolfgang; Vogelhuber, Martin; Heudobler, Daniel.
Afiliación
  • Fante MA; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Harrer DC; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Zartner B; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Lüke F; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Mayer S; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
  • Menhart K; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Reichle A; Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.
  • Herr W; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Vogelhuber M; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Heudobler D; Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Front Oncol ; 13: 1177330, 2023.
Article en En | MEDLINE | ID: mdl-37305564

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania